Investigating the effect of magnesium sulfate nebulization in children with cystic fibrosis
Phase 3
Recruiting
- Conditions
- Cystic fibrosis.Cystic fibrosis with pulmonary manifestationsE84.0
- Registration Number
- IRCT20231031059919N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
Suffering from cystic fibrosis
Over 6 years old
Ability to perform spirometry
FEV1 above 60%
Exclusion Criteria
Nnon-cooperation in the continuation of the intervention
Drug intolerance
Nebulizer intolerance
The patient's entry into the exacerbation phase
Inability to perform spirometry
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FEV1 index of spirometry in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;Spirometric FVC index in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;Spirometric FEV1/FVC index in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;Spirometric FEF25-75 index in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.;The score obtained from the Schwach-Man instrument in children with cystic fibrosis. Timepoint: At the beginning of the intervention and after 4 weeks at the end of the intervention. Method of measurement: Spirometry.
- Secondary Outcome Measures
Name Time Method . Timepoint: . Method of measurement: .